Based on these findings, we propose that combination treatment with inhibitors for Wnt/β-catenin and YAP/TAZ signaling may offer a potential therapeutic avenue for HCC tumors harboring AXIN1 mutations.61 The gene discussed is AXIN1; the disease is hepatocellular carcinoma.